Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.

ABSTRACT:

Background

Pancreatic adenocarcinoma (PDAC) remains a refractory disease; however, modern cytotoxic chemotherapeutics can induce tumor regression and extend life. A blood-based, pharmacogenomic, chemosensitivity assay using gene expression profiling of circulating tumor and invasive cells (CTICs) to predict treatment response was previously developed. The combination regimen of 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) and gemcitabine/nab-paclitaxel (G/nab-P) are established frontline approaches for treating advanced PDAC; however, there are no validated biomarkers for treatment selection. A similar unmet need exists for choosing second-line therapy.

Methods

The chemosensitivity assay was evaluated in metastatic PDAC patients presenting for frontli

SUBMITTER: Yu KH 

PROVIDER: S-EPMC10131181 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature